Skip to Content
US Videos

4 Companies Leading the Next Wave of Cancer-Drug Innovation

First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.

Mentioned: , , ,

Matt Coffina: For Morningstar StockInvestor, I'm Matt Coffina. I am joined today by Damien Conover, who is the director of our health-care team. We are going to talk about immuno-oncology drugs.

Damien, thanks for joining me.

To view this article, become a Morningstar Basic member.

Register for Free

Matthew Coffina does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.